Europe Organoids Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Stomach, Intestine, Liver, Pancreas, Lung, Brain, Kidney, and Others), Application (Developmental Biology, Disease Pathology of Infectious Disease, Regenerative Me

Europe Organoids Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Type (Stomach, Intestine, Liver, Pancreas, Lung, Brain, Kidney, and Others), Application (Developmental Biology, Disease Pathology of Infectious Disease, Regenerative Medicine, Drug Toxicity & Efficacy Testing, Drug Discovery & Personalized Medicine, and Others), and Source (Pluripotent Stem Cells and Organ-specific Adult Stem Cells)

The Europe organoids market is expected to grow from US$ 1,018.12 million in 2023 to US$ 2,718.25 million by 2028. It is estimated to record a CAGR of 21.7% from 2023 to 2028.

Growing Adoption of Personalized Drugs Fuels Europe Organoids Market

Personalized medicine, also known as precision medicine, is a medical model that practices procedures or drugs tailored to the individual patient based on the projected response or risk of disease.

The implementation of organoids to create personalized drug therapies provides exciting opportunities for improving patient care. In addition, pharmacists play an essential role in increasing the demand for personalized medicines as they proactively educate and create awareness about precision medicine. This demand has persuaded pharmaceutical research to develop more tailored treatments to make medicines safer and more effective.

Personalized cancer medicine is an approach to tailoring effective therapeutic strategies for each patient according to a tumor’s genomic characterization. There is an increasing demand for research in personalized tumor modeling to confirm the functional aspects of genomic drug response predictions in the preclinical setting. Numerous studies have highlighted the application of tumor organoids in personalized cancer medicine in terms of gene-drug association treatment, identification of new therapies, and prediction of patient outcomes.

Personalized cancer therapy applies specific treatments to each patient. Using personalized tumor models with similar characteristics to the original tumors may result in accurate predictions of drug responses in patients. Tumor organoid models have several advantages, such as conserving the molecular and cellular composition of the original tumor over pre-existing models. These advantages highlight the tremendous potential of tumor organoids in personalized cancer therapy, particularly in preclinical drug screening and predicting patient responses to selected treatment regimens.

Europe Organoids Market Overview

The Europe organoids market is segmented into Germany, France, Italy, the UK, Spain, and the Rest of Europe. The market growth is associated with the rising demand for tissue engineering and organ transplantation; increasing adoption of organoids for disease modeling, gene mutation, and tumor modeling; and growing research activities on organoids. In addition, factors such as increased funding and public-private investments are likely to offer more opportunities to market players in the coming years.

Europe Organoids Market Revenue and Forecast to 2028 (US$ Million

Europe Organoids Market Segmentation

The Europe organoids market is segmented on the basis of type, application, source, and country.

Based on type, the market is segmented into stomach, intestine, liver, pancreas, lung, brain, kidney, and others. The intestine segment registered the largest market share in 2023.

Based on application, the Europe organoids market is segmented into developmental biology disease, pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. The developmental biology disease segment held the largest market share in 2023.

Based on source, the Europe organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cells. The pluripotent stem cells segment held a larger market share in 2023.

Based on country, the Europe organoids market is segmented into Germany, France, the UK, Italy, Spain, and the Rest of Europe. Germany dominated the market share in 2023.

Cellesce Ltd; Corning Inc; Definigen; Hubrecht Organoids Technology; InSphero; Merck kGaA; Organoid Therapeutics; PeproTech, Inc.; STEMCELL Technologies Inc; and Thermo Fisher Scientific Inc are the leading companies operating in the organoids market in Europe.

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe organoids market.
Highlights key business priorities in order to assist companies to realign their business strategies
The key findings and recommendations highlight crucial progressive industry trends in the Europe organoids market, thereby allowing players across the value chain to develop effective long-term strategies
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the organoids market, as well as those hindering it
Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution